Innovative healthcare delivery for patients with asthma using digitally supported self-management: A pilot study in secondary care

Innovative healthcare delivery for patients with asthma using digitally supported self-management: A pilot study in secondary care - Astmakompas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON53444

Enrollment

Registered

2022-06-24

Start date

2022-11-21

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

Astmakompas is a CE-certified eHealth application for patients with asthma. The platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The pat

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: • Being aged 18 years or older • Not having used Astmakompas before • Having a physician diagnosis of asthma • Having uncontrolled asthma as defined by a score of >= 1.5 on the Asthma Control Questionnaire • Being able to understand, read and speak the Dutch language (i.e., based on self-report) • Having access to the Internet and a smartphone

Exclusion criteria

Exclusion criteria: • Having a respiratory disease other than asthma • Having a non-reversible airway obstruction

Design outcomes

Primary

Measure	Time frame
Primary study parameters include the Feasibility of Intervention Measure (FIM), the Acceptability of Intervention Measure (AIM, only administered in HCPs), objective user patterns of Astmakompas, the Client Satisfaction Questionnaire-8 (CSQ-8, only administered in patients), the System Usability Scale (SUS, administered in both HCPs and patients), and adverse events (assessed in patients). Qualitative assessment in patients and HCPs will give a more in-depth understanding of feasibility, acceptability, usability and safety of Astmakompas.	—

Measure

Time frame

Primary study parameters include the Feasibility of Intervention Measure (FIM), the Acceptability of Intervention Measure (AIM, only administered in HCPs), objective user patterns of Astmakompas, the Client Satisfaction Questionnaire-8 (CSQ-8, only administered in patients), the System Usability Scale (SUS, administered in both HCPs and patients), and adverse events (assessed in patients). Qualitative assessment in patients and HCPs will give a more in-depth understanding of feasibility, acceptability, usability and safety of Astmakompas.

—

Secondary

Measure	Time frame
Secondary study parameters, all assessed in patients, include asthma control (assessed using the Asthma Control Questionnaire [ACQ] and the weekly monitoring questionnaire that is part of Astmakompas), lung function as assessed by the spirometer, illness-related quality of life as assessed by the Respiratory Illness questionnaire-Monitoring 10 (RIQ-MON10), generic quality of life as assessed by the EuroQol 5 dimensions 5 levels (EQ-5D-5L), the Perceived Control of Asthma Questionnaire (PCAQ), and direct and indirect costs as assessed by items from the iMTA Productivity Cost Questionnaire (iPCQ) and iMTA Medical Consumption Questionnaire (iMCQ). Additionally, qualitative assessment in patients and HCPs will give a more in-depth understanding of direct and indirect costs.	—

Measure

Time frame

Secondary study parameters, all assessed in patients, include asthma control (assessed using the Asthma Control Questionnaire [ACQ] and the weekly monitoring questionnaire that is part of Astmakompas), lung function as assessed by the spirometer, illness-related quality of life as assessed by the Respiratory Illness questionnaire-Monitoring 10 (RIQ-MON10), generic quality of life as assessed by the EuroQol 5 dimensions 5 levels (EQ-5D-5L), the Perceived Control of Asthma Questionnaire (PCAQ), and direct and indirect costs as assessed by items from the iMTA Productivity Cost Questionnaire (iPCQ) and iMTA Medical Consumption Questionnaire (iMCQ). Additionally, qualitative assessment in patients and HCPs will give a more in-depth understanding of direct and indirect costs.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026